Sep 9, 2024 at 11:00 AM EDT
Investor Relations
Bionano Genomics, Inc. (NASDAQ: BNGO) seeks to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual and institutional investor includes stock price and history, upcoming events and presentations and financial documents.
Minimum 15 minutes delayed. Source:
Erik Holmlin is a dynamic leader with more than two decades of experience developing innovative solutions and companies in the life sciences and health care industries.
Erik’s experience includes positions at GenVault Corporation (CEO), Exiqon A/S (CCO) and Becton Dickinson (vice president of marketing and development). In 2001, Erik led the formation and financing efforts of GeneOhm Sciences, Inc. and orchestrated the company’s acquisition by Becton Dickinson in 2006. He also served as an entrepreneur in residence (EIR) at leading life-science venture capital firm Domain Associates, LLC.
Erik was a National Institutes of Health postdoctoral fellow at Harvard University and a National Science Foundation predoctoral fellow at the California Institute of Technology, Pasadena (Caltech). He holds a PhD in chemistry from Caltech and MBAs from UC Berkeley and Columbia University.
Mark Oldakowski has a 20-year history of success in the development of systems for the life sciences and medical device industries.
Prior to joining Bionano Genomics, Mark led a global team at Brooks Life Science Systems in the development of sample analyzers, high-throughput screening solutions, and chemical storage and biobank systems. Prior to his time at Brooks, Mark was with Affymetrix, where he launched the array platform that is widely used today for GWAS and other genomics applications. Mark also spent time at Siemens Healthcare Diagnostics on the development of equipment for diagnostic core labs. During his 13 years at Life Technologies (formerly Applied Biosystems) he held various levels of responsibility in the development of systems for real-time PCR, sequencing and sample preparation. Mark holds a bachelor’s degree in electrical engineering and a master’s degree in computer and systems engineering from Rensselaer Polytechnic Institute in New York.
Alka Chaubey is double board-certified in clinical cytogenetics/genomics and clinical molecular genetics/genomics by the American Board of Medical Genetics and Genomics (ABMGG).
Previously, she was the Head of Cytogenomics at PerkinElmer Genomics, where Dr. Chaubey led the successful development and launch of several innovative products including the CNGnome test (low-pass whole genome sequencing), and a new FSHD assay utilizing Saphyr. She has also played an integral role on Vanadis team at PerkinElmer in their efforts to bring a new PCR-free NIPT technology to the market. Prior to PerkinElmer Genomics, Dr. Chaubey was the Director of the Cytogenomics Laboratory at the Greenwood Genetic Center, SC, USA. She also holds an academic appointment as the Scientific Director of the Georgia Esoteric and Molecular Laboratory, Scientific Director of the Cytogenetics Laboratory of the Augusta University Medical Center and Adjunct Assistant professor of Pathology of the medical College of Georgia at Augusta University.
Stan Marin is a sales leader with more than 20 years of experience driving fast-growing capital equipment businesses and cutting-edge technologies adoption in the life sciences and molecular biology diagnostics industries.
Prior to joining Bionano, where he has held different sales leadership positions covering EMEA, APAC and global regions, Stan led a sales and support team at Fluidigm, bringing the sales of microfluidic systems for high-throughput qPCR and single-cell analysis from the early stages to complete adoption on the French market. Before that, he also led sales development successes at Pyrosequencing-Biotage and then Qiagen on the emerging next-generation sequencing (NGS) market for single-nucleotide polymorphism (SNP) genotyping and methylation analysis.
Stan received his Master of Science in biology from University Pierre et Marie Curie – Paris 6 and his MBA from IAE Paris, business school of the University Pantheon-Sorbonne – Paris 1.
Donna Polizio has over 30 years of experience working in diagnostic and life sciences companies including Hologic, Redpath, Aureon and Genomic Health, where she held leadership roles in areas including research and development, applications, sales and market access, with a special emphasis in In-Vitro Diagnostics (IVD) and Laboratory Developed Tests (LDTs).
She joined Bionano from Exact Sciences, where she most recently held the role of Vice President, U.S. Managed Care and Reimbursement. Donna has obtained coverage and reimbursement for some of the most valued diagnostics of the last several decades. She received a bachelor’s degree in biology from Queens College and a master’s degree in organizational leadership from Mercy College.
Alex Hastie is a PhD trained scientist who has focused on scientific advances in optical genome mapping for the past 12 years.
Alex received training during his PhD in cancer genetics, biochemistry, and biophysics at the Roswell Park Cancer Institute. He focused his research on novel technology and received a patent as coinventor for a method for detection of protein-protein interactions.
After a post-doctoral fellowship at the Max Planck Institute in Munich, Germany, he joined Bionano Genomics as a scientist, where he has been an inventor on multiple patents and coauthored over 90 peer reviewed publications. Currently, Alex serves as vice president of clinical and scientific affairs where he leads clinical trials and the company’s scientific publication portfolio.
Viren Wasnikar has over 20 years of experience in the field of genomics, building data analysis and visualization products. Prior to joining Bionano, Viren managed a suite of BioDiscovery software products for analysis and interpretation of all genomic variants from microarray and next-generation sequencing (NGS) data.
During his two decades of experience in the life sciences field, Viren has demonstrated the ability to build robust, high-performing applications that have become industry standards. He has held various software development responsibilities in the areas of image analysis, machine learning and software engineering. He has successfully led software engineering teams with a firm belief in pursuing excellence. Viren holds a bachelor’s degree in electronic engineering from Poona University in India and a Master of Science degree in computer science from the University of Texas.
Mike Stringfellow has more than 25 years of experience helping biotechnology companies build exceptional Customer Solutions teams that enable customers’ success.
Mike came to Bionano Genomics after a successful five years at Agena Bioscience where he served as the global leader of Customer Solutions. Mike rebuilt the CS team from the ground up to enable the company’s commercial success which culminated in the successful acquisition of Agena by Mesa Laboratories in 2021. Prior to Agena, Mike spent more than 20 years as a part of Applied Biosystems/Life Technologies/Thermo Fisher organizations, leading a variety of teams in Customer Solutions, Product & Project Management and Operations. During his time at Applied Biosystems, Mike was certified as a Six Sigma Black Belt and completed course work to achieve Project Management certification. Mike holds a Bachelor of Science degree in molecular biology from the University of Utah.
Jonathan Dixon is an experienced legal advisor with over two decades of experience counseling leading life science and medical device companies in intellectual property, technology transactions, and M&A.
Prior to joining Bionano Genomics, Jonathan held a variety of legal positions, including associate general counsel, intellectual property at Becton, Dickinson and Company (“BD”) and CareFusion, and assistant general counsel and director of legal at BD and GeneOhm Sciences. Jonathan holds bachelor’s degrees in microbiology and economics from Brigham Young University, and a juris doctor degree from Lewis & Clark Law School.
Mark Adamchak is a resourceful accounting leader with 20 years of experience in financial management and operational roles, primarily in mid to large-sized corporations.
Mark’s skillset includes building high-performance teams, technical accounting, public company reporting, Sarbanes Oxley, M&A integrations, business process reengineering and cash flow management. Mark started his career as an auditor at KPMG and has since served in a broad range of progressive roles, most notably at SAIC, Intuit, and a private, life sciences start-up, Pathway Genomics. Mark joined Bionano as a controller in June 2018 and led the accounting function through a successful IPO in October 2018. Since then, he has contributed to over $450M in debt and equity raises and elevated his team to achieve SOX compliance as a Large Accelerated Filer. Mark is a licensed CPA and earned his bachelor’s degree in accounting at James Madison University.
Cory Kreeck is a people leader and human resources executive with 25 years of experience leading global teams across business functions. He brings a people-focused and entrepreneurial approach to human resources.
Prior to Bionano, Cory led human resources efforts at SpinLaunch, where he was Head of People, and Beachbody, where he held a number of roles with increasing responsibility, including Group Vice President, People Operations. Cory received a Bachelor of Science in philosophy from Utah State University and a master’s degree in organizational leadership from Biola University. Cory is also a Professional Certified Coach with the International Coaching Federation.
With more than 30 years of experience in the medical and veterinary diagnostics industry, Todd Woodring has helped develop and manufacture a wide array of products related to microbiology, endocrinology, and vector-borne diseases in both humans and animals. From 2020 to 2023, Todd served as Vice President of Operations at Alpha Teknova Inc., a CDMO focused company supplying custom products for the biopharmaceutical, diagnostics and cell and gene therapy markets. From 2014 until December 2020, Todd was Vice President of Laboratory Operations at Telomere Diagnostics (acquired by Orig3n, Inc.), a CLIA-certified clinical laboratory that specialized in direct-to-consumer genetic testing and qPCR based COVID-19 testing. Prior to Telomere Diagnostics, Todd served as Vice President of Manufacturing Operations at Antech Diagnostics, where he developed and directed in-house assay development, manufacturing, and supply chain functions.
Todd also held senior level manufacturing and operations positions at American Hospital, Baxter Healthcare, Dade-Behring, Chiron, Bayer, and Quest Diagnostics. He received a bachelor’s degree in biological sciences with an emphasis in microbiology from the University of California, Davis and completed post graduate work in epidemiology, immunology, and microbiology, culminating in a Clear Ryan Teaching Credential.